title: The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients.
abstract: Cardiotoxicity has been feared as a potential side effect of imatinib therapy. Studies with short-term follow-up failed to identify an excess of cardiac events, but longer-term observations are needed to more definitely exclude this adverse effect. This study was designed to assess the cardiac effects of imatinib in patients under long-term treatment. We included 90 chronic myeloid leukaemia (CML) patients under imatinib therapy for a median treatment time of 3.3 years (mean age 48.9 ± 15.1 years). Patients underwent clinical evaluation, electrocardiography, echocardiography (two-dimensional, colour flow, tissue Doppler and strain imaging), brain natiuretic peptide (BNP) and troponin I measurements. Twenty healthy volunteers were included as a control group for strain measurements. The mean ejection fraction was 68 ± 7% and the median BNP level was 9.6 pg/ml (interquartile range [IQR] 5.7-17.0 pg/ml). Two patients had either an elevated BNP or a depressed ejection fraction (2.2%; 90%CI 0.9-6.8%). Most of troponin I measurements were lower than the detection limit, except for two patients. Longitudinal strain was similar to measurements in healthy controls. A weak relation was observed between log BNP and imatinib treatment duration and dose. There was no relation between these variables and left ventricle ejection fraction. In conclusion, matinib-related cardiotoxicity is an uncommon event in CML patients, even during long-term treatment. Therefore, its use should not be cause of great concern, and the usefulness of regular cardiac monitoring all patients while on imatinib therapy is questionable.
authors.affiliation: School of Medicine, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. milenamarc@gmail.com
authors.forename: Milena S
authors.initials: MS
authors.lastname: Marcolino
authors.forename: Eric
authors.initials: E
authors.lastname: Boersma
authors.forename: Nelma C D
authors.initials: NC
authors.lastname: Clementino
authors.forename: Maria do Carmo P
authors.initials: Mdo C
authors.lastname: Nunes
authors.forename: Márcia M
authors.initials: MM
authors.lastname: Barbosa
authors.forename: Maria Helena C R
authors.initials: MH
authors.lastname: Silva
authors.forename: Marcel L
authors.initials: ML
authors.lastname: Geleijnse
authors.forename: Antonio L
authors.initials: AL
authors.lastname: Ribeiro
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001549:Benzamides; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D004334:Drug Administration Schedule; D004452:Echocardiography; D005260:Female; D006321:Heart / Q000187:drug effects*; D006333:Heart Failure / Q000097:blood / Q000139:chemically induced* / Q000000981:diagnostic imaging; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D020097:Natriuretic Peptide, Brain; D000068877:Imatinib Mesylate